Oculis has signed an agreement to acquire the worldwide rights to drug candidates Privosegtor and ACT-02 from Accure Therapeutics [1, 2].
The acquisition allows Oculis to expand its portfolio of treatments for neurological eye conditions. By securing these assets, the company aims to increase its strategic flexibility and establish itself as a leader in the neuro-ophthalmology sector [2].
Under the terms of the asset purchase agreement, Oculis will pay $3.8 million plus shares to Accure Therapeutics [1]. The deal focuses on the lead candidate, Privosegtor, also known as ACT-01, as well as the secondary candidate ACT-02 [1, 2].
Oculis is positioning the move as a way to fortify its presence in a specialized area of medicine. The company is targeting the development of therapies that address the intersection of neurology and ophthalmology, a field often underserved by larger pharmaceutical firms [2].
Accure Therapeutics will transfer all global rights for these specific candidates to Oculis. This transfer includes the intellectual property, and development rights necessary to move the candidates through further clinical stages [1, 2].
“Oculis will pay $3.8 million plus shares to Accure Therapeutics.”
This acquisition represents a targeted expansion into neuro-ophthalmology, a niche medical field. By acquiring early-stage candidates like Privosegtor, Oculis is betting on specialized drug development to differentiate itself from broader ophthalmic competitors, though the success of the move depends on the clinical efficacy of the ACT-01 and ACT-02 candidates.
